Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Reata Pharmaceuticals Inc

CUSIP: 75615P953 | 8 institutional holders

Quarters

Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile